Abeona Therapeutics

Abeona Therapeutics Inc. (Nasdaq: ABEO) is a leading clinical stage company developing gene therapy and plasma-based therapies for severe and life-threatening rare genetic diseases. Abeona's lead programs are ABO-102 (AAV-SGSH) and ABO-101 (AAV-NAGLU), adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome (MPS IIIA and IIIB), respectively. We are also developing ABO-201 (AAV-CLN3) gene therapy for juvenile Batten disease (JBD); and ABO-301 (AAV-FANCC) for Fanconi anemia (FA) disorder using a novel CRISPR/Cas9-based gene editing approach to gene therapy program for rare blood diseases. In addition, Abeona is developing plasma protein therapies, including SDF Alpha™ (alpha-1 protease inhibitor) for inherited COPD, using our proprietary SDF™ (Salt Diafiltration) ethanol-free process.

Type
Public
HQ
Dallas, US
Founded
2013
Size (employees)
6 (est)
Abeona Therapeutics was founded in 2013 and is headquartered in Dallas, US

Abeona Therapeutics Office Locations

Abeona Therapeutics has an office in Dallas
Dallas, US (HQ)
600 3333 Lee Pkwy

Abeona Therapeutics Metrics

Abeona Therapeutics Financial Metrics

Revenue (2015)

$1 m

Revenue growth (2014-15), %

12%

Net income (2015)

($14.5 m)

Market capitalization (28-Apr-2017)

$227.4 m

Closing share price (28-Apr-2017)

$5.6

Cash (31-Dec-2015)

$40.1 m
Abeona Therapeutics's current market capitalization is $227.4 m.
Abeona Therapeutics's revenue was reported to be $1 m in FY, 2015 which is a 12% increase from the previous period.
FY, 2013FY, 2014FY, 2015

Revenue

$2 m$925 k$1 m

Revenue growth, %

(55%)12%

Operating expense total

$5.8 m$4.1 m$19.6 m

EBIT

($3.8 m)($3.1 m)($18.5 m)

EBIT margin, %

(186%)(338%)(1783%)

Net Income

$4.4 m($26.8 m)($14.5 m)
FY, 2013FY, 2014FY, 2015

Cash

$424 k$11.5 m$40.1 m

Accounts Receivable

Inventories

$77 k$315 k

Current Assets

$575 k$11.6 m$40.6 m

PP&E

$6 k$4 k$350 k

Goodwill

$32.5 m

Total Assets

$613 k$16.6 m$80.1 m

Accounts Payable

$863 k$1.9 m$875 k

Dividends Payable

$6.7 m

Current Liabilities

$9 m$2.9 m$1.5 m

Additional Paid-in Capital

$251.4 m$300.7 m$378 m

Retained Earnings

($266.4 m)($296.1 m)($310.6 m)

Total Equity

($14.8 m)$4.8 m$67.7 m

Financial Leverage

0 x3.4 x1.2 x
FY, 2013FY, 2014FY, 2015

Net Income

$4.4 m($26.8 m)($14.5 m)

Depreciation and Amortization

$3 k$11 k$551 k

Accounts Receivable

Inventories

$174 k$77 k($287 k)

Accounts Payable

($1.2 m)$33 k($1.2 m)

Cash From Operating Activities

$1 k($1.6 m)($10.4 m)

Capital Expenditures

($2 k)($308 k)

Cash From Investing Activities

($2 k)$3.4 m

Cash From Financing Activities

$29 k$12.7 m$35.7 m

Interest Paid

$7 k$7 k

Free Cash Flow

$3 k($10.1 m)

Abeona Therapeutics Market Value History

Abeona Therapeutics Online Presence

Abeona Therapeutics Company Life

You may also be interested in